“iCAD is focused on helping clinicians find the most prevalent cancers by detecting areas of concern, improving workflow and providing early diagnosis for patients worldwide,” said Ken Ferry, President and CEO of iCAD. “We have received great support from U.S. and European radiologists for our Computer-Aided Detection (CAD) products for digital and analog mammography as well as for breast and prostate MRI. This year we are expanding into CTC, also known as virtual colonoscopy, which we expect will have a positive impact on the number of patients undergoing this important diagnostic procedure.”
At ECR, iCAD will showcase several image analysis and clinical decision support solutions that work in combination with MRI and CT imaging modalities.
* SpectraLook™ and VividLook™ use innovative algorithms that generate colorized MRI images and enhancement curves on a pixel-by-pixel basis, providing radiologists with timely and efficient contrast kinetic assessment of lesions in the breast and prostate; * CADvue™ is a complete MRI image review, analysis and BI-RADS® compatible reporting solution providing contrast enhancement curves, dynamic 3D images and quantification of key lesion parameters. CADvue’s automation of critical manual steps provides a significant reduction in the time required to generate curves, and it streamlines radiologists’ work flow and diagnosis; * VeraLook™ is a revolutionary CAD solution for virtual colonoscopy (CTC) designed to aid radiologists in the detection of polyps during their review of CTC exams. Early clinical evidence suggests that CAD for CTC will enhance radiologists’ effectiveness in interpreting CTC studies.*
CTC employs cutting-edge, virtual reality technology to produce three-dimensional images that permit a thorough yet minimally invasive evaluation of the entire colorectal structure. iCAD’s VeraLook technology uses advanced algorithms to highlight suspicious polyps warranting closer review by a radiologist. In addition, VeraLook has the potential to reduce oversight errors that can occur during a virtual colonoscopy study review due to the large number of images generated by the CT system – often exceeding 1,000 images for a single patient.
CTC is an accurate alternative to colonoscopy for polyp detection. Since virtual colonoscopy requires no sedation, people receiving a CTC exam are able to return to their normal activities immediately following the examination. By incorporating CAD with virtual colonoscopy, radiologists have the option of using an image analysis tool that may aid them in detecting early-stage polyps as they are provided a list of CAD marks with potential polyp locations clearly marked for their inspection.
iCAD will also demonstrate elements of their next generation SecondLook Digital CAD solution currently under development. Advances shown will include performance improvements, software enhancements, and new “lesion metrics” that provide insight into CAD’s decision making process. iCAD’s industry-leading SecondLook Digital CAD system offers unique compatibility with industry leading Full-Field Digital Mammography (FFDM) solutions – both Digital Radiography (DR) and Computed Radiography (CR). iCAD will also demonstrate customized CAD solutions for Agfa CR**, Sectra**, Philips CR** and Planmed** full-field digital mammography systems. SecondLook Digital CAD broadens and strengthens these solutions by providing enhanced detection and workflow capabilities.
All of these products will be featured at the iCAD booth, #536, located at Austria Center Vienna, Expo E.
* Investigational Device. Limited by Federal Law to Investigational Use.
**Only available internationally
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Currently available in more than 2,700 healthcare centers worldwide, iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
Contact:
For iCAD: Darlene Deptula-Hicks, 603-882-5200 x7944 ddeptula@icadmed.com or For Investor Relations: Lippert/Heilshorn & Associates Anne Marie Fields, 212-838-3777 x6604 afields@lhai.com or For media inquiries: MS&L PR Liza Heapes, 617-937-2829 liza.heapes@mslpr.com
